We discuss some of the anticipated multiple myeloma trials with Sagar Lonial, MD, ahead of the 2015 American Society of Clinical Oncology Annual Meeting.

Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.

In this podcast ahead of the 2015 ASCO Annual Meeting, we discuss CT screening for individuals with a high risk for lung cancer with Claudia I. Henschke, MD, PhD.

As part of our coverage of the ONS Annual Congress, we discuss some of the unique psychosocial challenges faced by young adults with cancer.

As part of our coverage of the ONS Annual Congress, we are discussing the oncology nurse's role in distress screening in cancer patients.

As part of our coverage of the 2015 ONS Annual Congress, we discuss genetic testing for cancer patients and the role of oncology nurses.

Ahead of the 2015 AACR Annual Meeting we discuss how insulin resistance relates to current cancer therapies.

In this interview we discuss the recent CMS decision to cover low-dose CT screening for lung cancer in patients who fit specific criteria.

In this interview we discuss the current guidelines for lymph node staging in breast cancer and dive into the debate surrounding sentinel node biopsies.

In this interview we discuss the changing landscape of systemic therapies for the treatment of bladder cancer.

As part of our coverage of the ASCO GU Cancers Symposium, we discuss decision-making in the management of patients with early-stage prostate cancer.

As part of our MBCC coverage, we discuss how physicians can improve the patient experience through pain control both during and after breast cancer treatment.

As part of our MBCC coverage we discuss MRI screening for breast cancer in patients who carry a BRCA mutation or have a first-degree relative who is a BRCA carrier.

In this interview we discuss how patient adherence to the American Cancer Society’s cancer prevention guidelines affects cancer risk and mortality.

According to three associated and recently published large randomized studies, while about 75% of cancer patients with major depression do not receive any treatment for their depression, a new system of integrating depression treatment into cancer patient care can transform patient outcomes.

In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.

In this preview of the 2014 San Antonio Breast Cancer Symposium, we take a look at some of the studies to watch for at this year's event.

Ahead of the 2014 ASH Annual Meeting & Exhibition we discuss current treatment strategies for elderly patients with acute myeloid leukemia.

In this interview we discuss a patient who experienced regression of BRAF-inhibitor-induced eruptive melanocytic nevi following concomitant addition of a MEK inhibitor.

As part of our Society of Neuro-Oncology annual meeting coverage, we discuss quality of life issues and neurologic rehabilitation in patients with neuro-oncologic diseases.

In this interview we discuss the link between soy consumption and breast cancer, and the impact of soy supplements on gene expression in early-stage disease.

In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.

As part of our coverage of the 2014 ESMO meeting we discuss recent advances in the treatment of kidney, bladder, and testicular cancers.

In this interview we discuss the American Society of Clinical Oncology’s (ASCO) health information and patient record initiative called CancerLinQ.

As part of our coverage of the ASCO Breast Cancer Symposium we discuss the clinical meaningfulness of pathologic complete response as a surrogate endpoint in breast cancer clinical trials.

Ahead of the 2014 ASCO Breast Cancer Symposium we discussed genetic and environmental risk factors for breast cancer, as well as interventions that can reduce a patient’s risk.

Following studies that found no survival or mortality benefit, we discuss the utility of primary androgen deprivation therapy in localized prostate cancer.

In light of the recent FDA approval of HPV testing for women as a screening method for cervical cancer, we discuss changing guidelines with two experts.

As part of our coverage of the 2014 ASCO Annual Meeting, we discuss treatment strategies for breast cancer patients who harbor either the BRCA1 or BRCA2 mutation.

As part of our coverage of the ASCO Annual Meeting, we discuss advances in the management of upper gastrointestinal (GI) tract tumors, as well as highlighting clinical trial results that will be reported at the meeting.